Elutia Inc. develops and commercializes drug-eluting biologic products for use in surgical implantation and tissue repair across multiple therapeutic areas. The company's portfolio includes biomaterial-based devices designed to address complications associated with cardiac implantable electronic devices, facilitate cardiac tissue repair, and support soft tissue reconstruction in orthopedic and reconstructive surgery applications. Products span EluPro and CanGaroo for cardiac device protection, ProxiCor and Tyke for cardiac tissue repair, VasCure for vascular reconstruction, and SimpliDerm for dermal and soft tissue applications including breast reconstruction and hernia repair.
The company operates across three business segments: Device Protection, Women's Health, and Cardiovascular. Elutia distributes its products through a combination of direct sales personnel, commercial partners, independent sales agents, and third-party distributors to hospitals and healthcare facilities primarily in the United States. The company is a commercial-stage developer with 51 full-time employees and operates from its headquarters in Silver Spring, Maryland. Elutia was incorporated in Delaware in 2015 under its former name, Aziyo Biologics, Inc., and rebranded to Elutia Inc. in September 2023.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.86 | $-1.86 | +10.1% | |
| 2023 | $-2.07 | $-2.07 | +13.0% | |
| 2022 | $-2.38 | $-2.38 | +0.0% | |
| 2021 | $-2.38 | $-2.38 | — | |
| 2020 | — | — | — |